查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1351057

到 2030 年膀胱过动症治疗市场预测 - 按类型、疾病类型、配销通路和地区进行的全球分析

Overactive Bladder Treatment Market Forecasts to 2030 - Global Analysis By Type, Disease Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球膀胱过动症治疗市场规模将达到 36 亿美元，预计到 2030 年将达到 48 亿美元，预测期内年复合成长率为 6.2%。

膀胱过动症症 (OAB) 会导致频繁且意外的排尿衝动，这可能是控制的挑战。您可能会在白天或晚上频繁地想小便，或者您可能会无意中漏尿。医疗专业人员可以透过分析症状并检查骨盆和直肠附近的器官来识别膀胱过动症。有多种方法可以治疗膀胱过动症。改变某些行为、使用药物和刺激神经都是可能的治疗方法。

根据2021年6月发表在《Krager Journal》上的一篇题为「Mechanism and Priority of Botulinum Neurotoxin A vs Sacral Neuromodulation」的难治性膀胱过动症论文，膀胱过动症在全球极为常见，整体患病11.8%。

神经系统疾病患病上升

多种药物用于治疗神经系统疾病，包括抗癫痫药物、抗精神病药物、止痛药和抗胆碱能药物。人口高龄化正在推动市场扩张，同时开发新药和设备的支出也在增加。此外，政府法规机构和私人组织预计将发起宣传活动，以增加公众对早期残疾诊断的了解。此外，由于开发平臺强劲，有效药物可望很快进入市场，推动市场扩张。

频繁的产品召回

很大一部分人口患有膀胱过动症，这是一种对生活品质有负面影响的慢性疾病。 OAB 治疗药物的频繁召回可能会阻碍未来年度的市场扩张。由于製造问题，Cipla 于 2021 年 6 月在美国召回了 7,228 瓶琥珀酸索利那新片剂。主要製药公司频繁召回自家公司产品，阻碍了市场扩张。

研发费用增加和新治疗方法的引入

製药和生物製药公司目前正在投资用于治疗膀胱过动症的尖端药物，预计将在整个预测期内推出。此外，超过 30 种 OAB 治疗候选药物目前正处于临床阶段。分为3个二期项目、7个三期项目和16个四期项目。由于如此强大的产品线以及最终推出的其他药物和治疗方法，预计膀胱过动症治疗市场将会成长。三星医疗中心正在研究 OAB 患者的潜在生物标记物，包括三磷酸腺苷 (ATP)、前列腺素 E2 (PGE2) 和神经生长因子 (NGF)。 OAB 治疗市场的参与者有望从这些进步带来的显着成长预测中受益。

缺乏普及知识

阻碍市场拓展的要素之一是阶段开发或预註册阶段的药品数量较少。此外，补充疗法的可用性、新兴市场缺乏医疗基础设施以及缺乏合格的医疗专家阻碍了整个预测期内的市场扩张。产品召回和严格的政府法规也阻碍了产业扩张。

COVID-19 的影响：

COVID-19的爆发对膀胱过动症领域的全球扩张产生了有益的影响。 COVID-19相关膀胱炎（CAC）大大加剧了患者的膀胱功能障碍，这也导致了其他器官的特定问题。这对疫情期间和疫情后的膀胱过动症药物市场产生了积极影响。同时，COVID-19 大流行已成为医疗保健系统面临的最大挑战之一。 COVID-19大流行的爆发导致生产设施部分或完全关闭，美国、中国、日本、印度和德国等主要国家都处于长期封锁措施之下。这对膀胱过动症药物的生产产生了轻微影响。

预计抗胆碱能药物领域在预测期内将是最大的

由于抗胆碱能药物是治疗膀胱过动症症候群的主要选择，抗胆碱能药物市场预计将出现良好的成长。此外，美国食品药物管理局对仿製药的快速产品核可正在支持抗胆碱能药物市场的扩张。此外，与侵入性手术和口服药物相比，最终用户对肉毒桿菌治疗的偏好预计将增加预测期内膀胱过动症治疗市场同一领域的发展潜力。

特发性膀胱过动症领域预计在预测期内年复合成长率最高

由于患者特发性膀胱过动症领域率上升以及对特发性特发性膀胱膀胱过动症症治疗的需求不断增加，预计特发性膀胱过动症部分在预测期内将出现最高的年复合成长率。另一方面，由于预计会增加膀胱过动症领域的神经系统疾病的增加，预计神经膀胱过动症症领域将在预测期内以最快的速度扩大。

比最大的地区

由于医疗保健领域强劲，预计北美将在预测期内占据最大的市场份额。此外，还有要素，例如膀胱过动症治疗的报销、随着高龄化而增加的发病率以及该地区存在重要的行业参与者。此外，预计该市场将受益于老年人口的增长以及该地区人口高龄化的大量存在。

复合年复合成长率最高的地区：

由于该地区製药公司的存在以及中国和印度等人口大国购买力的不断上升，预计欧洲在预测期内将出现最高的年复合成长率。此外，医疗保健支出的增加以及采用高科技製造技术来提高膀胱过动症治疗药物的产量对于该地区的药品生产商来说是充足的，该地区拥有最大的製药部门和最大的药品供应量，并且很容易取得原料。此外，工业基础设施正在扩大，可支配收入正在增加，国内公司正在该地区建立业务。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球膀胱过动症治疗市场：依类型

  • 抗胆碱能药物
    • 达非那新
    • 非索罗定
    • 奥昔布宁
    • 索利那新
    • 托特罗定
    • 曲司品
    • 其他抗胆碱能药物
  • 米拉贝隆
  • 肉毒桿菌
  • 神经调节
  • 其他治疗方法

第6章全球膀胱过动症治疗市场：依疾病类型

  • 神经源性膀胱过动症
    • 帕金森氏症
    • 中风
    • 多发性硬化症
    • 脊髓损伤
  • 特发性膀胱过动症
  • 其他类型的疾病

第7章全球膀胱过动症治疗市场：按配销通路

  • 医院药房
  • 药局和零售药局
  • 线上提供者
  • 其他配销通路

第8章全球膀胱过动症治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Dr. Reddy's Laboratories Ltd
  • Pfizer Inc.
  • Cipla Ltd
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Sumitomo Pharma Co., Ltd
  • Teva Pharmaceutical Industries Limited
  • Johnson & Johnson Services, Inc.
  • Medtronic
  • Sanofi
  • Uro Medical
  • Urovant Sciences
  • Macleods Pharmaceuticals Ltd
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Laborie
Product Code: SMRC23744

According to Stratistics MRC, the Global Overactive Bladder Treatment Market is accounted for $3.6 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 6.2% during the forecast period. The condition known as overactive bladder (OAB) results in frequent, unexpected urinal urges that can be challenging to control. One can experience frequent urges to urinate during the day and at night, as well as inadvertent pee loss. A medical professional can identify overactive bladder by analyzing the symptoms and physically inspecting the organs close to the pelvic and rectum. Various treatments are available to treat hyperactive bladder. Changing certain behaviors, using medicine, and nerve stimulation are all possible treatments.

According to the article published in Krager Journal titled "Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation" for refractory overactive bladder, in June 2021, overactive bladder is highly prevalent worldwide and found that its overall prevalence was 11.8%.

Market Dynamics:

Driver:

Rising prevalence of neurological conditions

Several drugs, including antiepileptics, antipsychotics, analgesics, and anticholinergics, are used to treat neurological illnesses. The aging population is driving market expansion, along with increased spending on the development of new drugs and devices. Additionally, government regulatory agencies and private groups are projected to launch awareness efforts to raise public knowledge of early disorder diagnosis. Additionally, effective medications will soon enter the market as a result of a robust development pipeline, which is expected to fuel market expansion.

Restraint:

Frequent product recalls

A large portion of the population suffers from overactive bladder, a chronic medical condition that has an adverse effect on quality of life. The expansion of the market could be hampered in the coming years by frequent recalls of OAB-treating medications. Due to production problems, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US in June 2021. Leading pharmaceutical corporations frequently recalling their products hurts the market's expansion.

Opportunity:

Increasing R&D spending and the introduction of new treatments

Pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. In addition, more than 30 OAB candidates are presently in clinical development pathways. These are divided into three Phase II, seven Phase III, and sixteen Phase IV projects. The market for treating overactive bladder is anticipated to grow as a result of this strong pipeline and the eventual introduction of additional medications and therapies. Samsung Medical Center is researching potential biomarkers in OAB patients, including adenosine triphosphate (ATP), prostaglandin E2 (PGE2), and nerve growth factor (NGF). Players in the OAB treatment market can anticipate benefiting from significant growth prospects as a result of such advances.

Threat:

Lack of knowledge about its prevalence

One of the things preventing the market from expanding is the dearth of medications in Phase III development or the pre-registration stages. Additionally, throughout the forecast period, market expansion is hampered by the availability of complementary therapies, a lack of healthcare infrastructure in developing nations, and a shortage of qualified specialists. Recalls of products and stringent government regulations are also impeding industry expansion.

COVID-19 Impact:

The COVID-19 outbreak had a beneficial effect on the expansion of the overactive bladder sector globally. The patient's bladder dysfunction was greatly exacerbated by COVID-19 association cystitis (CAC), which also caused issues unique to other organs. This had a favorable effect on the market for treatments for overactive bladder both during and after the epidemic. The COVID-19 epidemic, on the other hand, presented one of the greatest difficulties for the healthcare system. Due to the protracted lockdown in important nations like the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of production facilities. This had some impact on the production of drugs for overactive bladder.

The anticholinergics segment is expected to be the largest during the forecast period

The anticholinergics segment is estimated to have a lucrative growth, due to the primary choice of medications for treating overactive bladder syndrome is anticholinergics. Additionally, the U.S. Food and Drug Administration's quick product approvals for generic medications support the expansion of the anticholinergic market. Additionally, it has been predicted that a movement in end users' preferences of botox treatment over invasive surgery or oral drugs will increase the segment's development potential in the overactive bladder therapeutics market over the course of the projection year.

The idiopathic overactive bladder segment is expected to have the highest CAGR during the forecast period

The idiopathic overactive bladder segment is anticipated to witness the highest CAGR growth during the forecast period, due to rising rates of idiopathic overactive bladder in patients and rising demand for overactive bladder drugs for the treatment of idiopathic overactive bladder. The sector for neurogenic overactive bladder, on the other hand, is anticipated to expand at the quickest rate during the forecast period due to the rise in neurological diseases, which is predicted to increase the incidence of overactive bladder.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its robust healthcare sector. In addition, factors such as reimbursement for overactive bladder treatment, an increasing incidence of the condition with advancing age, and the presence of significant industry players in the region. Moreover, the market is set to benefit from the growing elderly population, and the substantial presence of an aging demographic in the region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, due to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Moreover, an increase in medical spending and the use of high-tech manufacturing techniques to enhance the production of drugs for treating overactive bladder with largest pharmaceutical sector and the largest supply of medicines, with easy access to a plentiful supply of raw materials for pharmaceutical product producers in this region. In addition, because of the expanding industrial infrastructure, rising disposable incomes, and established domestic company presence in the area.

Key players in the market:

Some of the key players profiled in the Overactive Bladder Treatment Market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc. , Cipla Ltd, Lupin, Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., AbbVie Inc., Alembic Pharmaceuticals Limited, Sumitomo Pharma Co., Ltd, Teva Pharmaceutical Industries Limited, Johnson & Johnson Services, Inc., Medtronic, Sanofi, Uro Medical, Urovant Sciences, Macleods Pharmaceuticals Ltd, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc. and Laborie

Key Developments:

In July 2022, Dr. Reddy's Laboratories introduced fesoterodine fumarate extended-release tablets, a therapeutic generic equivalent to Pfizer's Toviaz (fesoterodine fumarate) ER tablets in the United States for the treatment of overactive bladder.

In April 2022, Dr Reddy's launched generic Methylprednisolone Sodium Succinate for injection in US, The injection is the generic equivalent of SOLUMEDROL and has been approved by the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

In May 2022, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy.

Treatments Covered:

  • Anticholinergics
  • Mirabegron
  • BOTOX
  • Neuromodulation
  • Other Treatments

Disease Types Covered:

  • Neurogenic Overactive Bladder
  • Idiopathic Overactive Bladder
  • Other Disease Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Overactive Bladder Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Anticholinergics
    • 5.2.1 Darifenacin
    • 5.2.2 Fesoterodine
    • 5.2.3 Oxybutynin
    • 5.2.4 Solifenacin
    • 5.2.5 Tolterodine
    • 5.2.6 Trospium
    • 5.2.7 Other Anticholinergics
  • 5.3 Mirabegron
  • 5.4 BOTOX
  • 5.5 Neuromodulation
  • 5.6 Other Treatments

6 Global Overactive Bladder Treatment Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Neurogenic Overactive Bladder
    • 6.2.1 Parkinson's disease
    • 6.2.2 Strokes
    • 6.2.3 Multiple Sclerosis
    • 6.2.4 Spinal Cord Injuries
  • 6.3 Idiopathic Overactive Bladder
  • 6.4 Other Disease Types

7 Global Overactive Bladder Treatment Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Drug Stores and Retail Pharmacies
  • 7.4 Online Providers
  • 7.5 Other Distribution Channels

8 Global Overactive Bladder Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Dr. Reddy's Laboratories Ltd
  • 10.2 Pfizer Inc.
  • 10.3 Cipla Ltd
  • 10.4 Lupin
  • 10.5 Sun Pharmaceutical Industries Ltd.
  • 10.6 Astellas Pharma Inc.
  • 10.7 AbbVie Inc.
  • 10.8 Alembic Pharmaceuticals Limited
  • 10.9 Sumitomo Pharma Co., Ltd
  • 10.10 Teva Pharmaceutical Industries Limited
  • 10.11 Johnson & Johnson Services, Inc.
  • 10.12 Medtronic
  • 10.13 Sanofi
  • 10.14 Uro Medical
  • 10.15 Urovant Sciences
  • 10.16 Macleods Pharmaceuticals Ltd
  • 10.17 Endo International PLC
  • 10.18 Hisamitsu Pharmaceutical Co., Inc.
  • 10.19 Laborie

List of Tables

  • Table 1 Global Overactive Bladder Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Overactive Bladder Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Overactive Bladder Treatment Market Outlook, By Anticholinergics (2021-2030) ($MN)
  • Table 4 Global Overactive Bladder Treatment Market Outlook, By Darifenacin (2021-2030) ($MN)
  • Table 5 Global Overactive Bladder Treatment Market Outlook, By Fesoterodine (2021-2030) ($MN)
  • Table 6 Global Overactive Bladder Treatment Market Outlook, By Oxybutynin (2021-2030) ($MN)
  • Table 7 Global Overactive Bladder Treatment Market Outlook, By Solifenacin (2021-2030) ($MN)
  • Table 8 Global Overactive Bladder Treatment Market Outlook, By Tolterodine (2021-2030) ($MN)
  • Table 9 Global Overactive Bladder Treatment Market Outlook, By Trospium (2021-2030) ($MN)
  • Table 10 Global Overactive Bladder Treatment Market Outlook, By Other Anticholinergics (2021-2030) ($MN)
  • Table 11 Global Overactive Bladder Treatment Market Outlook, By Mirabegron (2021-2030) ($MN)
  • Table 12 Global Overactive Bladder Treatment Market Outlook, By BOTOX (2021-2030) ($MN)
  • Table 13 Global Overactive Bladder Treatment Market Outlook, By Neuromodulation (2021-2030) ($MN)
  • Table 14 Global Overactive Bladder Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Overactive Bladder Treatment Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 16 Global Overactive Bladder Treatment Market Outlook, By Neurogenic Overactive Bladder (2021-2030) ($MN)
  • Table 17 Global Overactive Bladder Treatment Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 18 Global Overactive Bladder Treatment Market Outlook, By Strokes (2021-2030) ($MN)
  • Table 19 Global Overactive Bladder Treatment Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 20 Global Overactive Bladder Treatment Market Outlook, By Spinal Cord Injuries (2021-2030) ($MN)
  • Table 21 Global Overactive Bladder Treatment Market Outlook, By Idiopathic Overactive Bladder (2021-2030) ($MN)
  • Table 22 Global Overactive Bladder Treatment Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 23 Global Overactive Bladder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 24 Global Overactive Bladder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 25 Global Overactive Bladder Treatment Market Outlook, By Drug Stores and Retail Pharmacies (2021-2030) ($MN)
  • Table 26 Global Overactive Bladder Treatment Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 27 Global Overactive Bladder Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.